The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

ALTON The statistics surrounding the incidence rate of lung cancer nationally, state-wide, and locally can literally take your breath away.According to ...

Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates. Click for my VSTM stock update.

In particular, the main program of this company is looking at the development of nanobody Lu-RAD204 for the treatment of patients with non-small cell lung cancer ... cause the stock price to ...

including metastatic colorectal cancer, non-small cell lung cancer, and various forms of ovarian cancer. It works by blocking blood supply to tumors. Jobevne marks Biocon Biologics’ seventh ...

Candel Therapeutics Inc. stock ended Wednesday deep in the ... Patients with non-squamous non-small cell lung cancer (NSCLC) showed the most potent response, with a mOS of 25.4 months in this ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and ...

The Milwaukee Brewers will hold a public ceremony honoring the life of longtime broadcaster Bob Uecker before their Aug. 24 ...

– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts –</p ...

Johnson & Johnson stock slipped Tuesday, even after the company reported first-quarter earnings that surpassed expectations and boosted its full-year sales forecast. The pharmaceutical and biotech ...

Osimertinib is used to treat non-small cell lung cancer (NSCLC) in patients who have certain types of abnormal EGFR ...